Lexaria Bioscience Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated August 16, 2016, covers events occurring on August 11, 2016. Lexaria Bioscience Corp., a Nevada corporation with principal offices in Vancouver, BC, Canada, reported the closing of a private placement equity financing and the enhancement of investor relations services.
Key Financial Metrics
- Gross Proceeds Raised: US$93,511.50
- Securities Issued: 1,558,525 equity units
- Unit Price: US$0.06 per unit (consisting of one common share and one warrant)
- Warrant Terms: Exercise price of US$0.14; two-year term
- Post-Issuance Share Count: 48,021,811 shares issued and outstanding
- Insider Subscription: US$27,000
- Service Contract Cost: US$35,931.50 for a one-year contract with Frontier Merchant Capital Group
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is a current report regarding specific corporate events rather than a periodic financial statement.
Material Changes
The primary material change is the increase in outstanding shares from the private placement, resulting in a total of 48,021,811 shares. Additionally, the company entered into a material definitive agreement to enhance services with Frontier Merchant Capital Group to facilitate market awareness and introductions to institutional and retail brokers.
Outlook, Management Commentary, and Risks
Use of Proceeds: All funds raised (US$93,511.50) are designated for the deployment and marketing of hemp-based food products, investor relations, general and administrative (G&A) expenses, and general working capital.
Restrictions: Securities issued are subject to a hold period of four months and one day in Canada, or six months and one day for resales into the USA under Rule 144. The securities were not registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption.
Regulatory Status: The Private Placement is subject to normal regulatory approvals.
Investor Verification Checklist
- Verify the final regulatory approval status of the private placement.
- Confirm the actual deployment of funds toward hemp-based food product marketing versus G&A expenses.
- Monitor the dilution impact of the 1,558,525 new units on existing shareholders.
- Review the specific deliverables and performance metrics of the enhanced Frontier Merchant Capital Group contract.
- Check for any subsequent filings regarding the exercise of warrants or resale of restricted shares.